AgeX expects promising Longevity future

Latest articles

The Alliance for Longevity Initiatives – fighting aging

Advancing legislation and policies that aim to increase healthy human lifespan. Longevity is a journey that would be good to imagine we're all taking together;...

Team builds first living robots – that can reproduce

AI-designed Xenobots reveal entirely new form of biological self-replication which could prove promising for regenerative medicine. Birds do it, bees do it... now even living...

Aging in place trailblazer focus – Carewell

Carewell – aiding individuals through their caregiving journey with empathy and knowledge. Over the coming weeks, we will be bringing you extracts from 7 trailblazer...

Humanpeople raising £700k for AI preventative health platform

Digital preventative health platform combines blood, DNA and microbiome testing to power up your healthspan with highly personalised supplements. DISCLOSURE: Longevity.Technology (a brand of...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

The Alliance for Longevity Initiatives – fighting aging

Advancing legislation and policies that aim to increase healthy human lifespan. Longevity is a journey that would be good to imagine we're all taking together;...

Team builds first living robots – that can reproduce

AI-designed Xenobots reveal entirely new form of biological self-replication which could prove promising for regenerative medicine. Birds do it, bees do it... now even living...

Aging in place trailblazer focus – Carewell

Carewell – aiding individuals through their caregiving journey with empathy and knowledge. Over the coming weeks, we will be bringing you extracts from 7 trailblazer...

Click the globe for translations.

In its end of year letter to shareholders, AgeX Therapeutics sees a bright future for the Longevity market.

Longevity.Technology: The days when aging was considered natural and inevitable are long gone. Now it’s a disease to be treated like any other. Investor interest is growing, putting pioneering companies in a perfect position to enjoy rapid and sustained growth.

AgeX Therapeutics, which pioneers cell therapy and tissue regeneration, took the opportunity to reflect on a busy year, which has seen it move into a new facility in San Francisco Bay, add to its board of directors, and start work on pluripotent stem cell lines with its immunotolerance UniverCyte technology.

As covered previously by Longevity.Technology, UniverCyte takes the company a step closer to the the goal of universal allogenic cells. The allogenic approach uses donor cells, rather than the patient’s own, and is superior in every way, but faces a substantial challenge in the rejection of cells from the host immune system.

Hypoimmunogenic/universal cells evade the body’s natural immune system and so can be given to patients without immunosuppressant drugs. AgeX feels that these technologies could have a transformative impact on the entire industry.

“We believe this gives us a strong competitive edge over other companies struggling with transplant rejection,” states the letter. “In the coming year, we plan to create a UniverCyte-modified pluripotent stem cell cGMP master cell bank, from which we could potentially derive any human cell type for our in-house product development programs or to provide cells to third party pharma companies to pursue other products.” [1]

The company’s position was strengthened by securing a patent for a method of generating induced pluripotent stem cells. These cells have been reprogrammed to retrace their developmental age and to regain the ability to form all of the young cells and tissue types in the body.

It’s another advance in what appears to be a rapidly evolving Longevity market, with a host of novel services hitting the market addressing the issue of human aging. Aging is, as AgeX CEO Dr Michael West told us, “almost certainly the greatest medical mystery we have ever faced,” and there is a huge amount of work being done to open up new avenues.

Going forward, one of the most promising of these, says AgeX, is partial cellular reprogramming. The company feels this opens up an entirely new field of pioneering therapeutics. It’s a revolution AgeX is banking on with partial cellular technology and other innovations.

Source: Google: Market Summary: AgeX Therapeutics Inc. NYSEAMERICAN: AGE

A quick look at the company’s stock price over the last 12 months echoes the comments made by Dr Aubrey de Grey in a recent interview. “The science in the anti-aging world is ready now, but the [public] investor sentiment doesn’t necessarily feel that yet.”

AgeX is in a confident place. It’s bringing to market ground breaking developments which address some of the key challenges facing the age tech marketplace. With interest growing, the company believes it is ideally placed to benefit from growing investor focus on the issues of Longevity and aging.

[1] https://investors.agexinc.com/news/news-details/2019/AgeX-Therapeutics-Issues-Year-End-Letter-to-Shareholders/default.aspx

Image credit: Immersion Imagery / Shutterstock
Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Related articles

Humanpeople raising £700k for AI preventative health platform

Digital preventative health platform combines blood, DNA and microbiome testing to power up your healthspan with highly personalised supplements. DISCLOSURE: Longevity.Technology (a brand of...

Apollo closes $180m for age-related disease innovations

Apollo Health Ventures fund will drive breakthrough innovations combating age-related diseases. Apollo Health Ventures has announced the final closing of its second venture fund to...

Aging in place: technologies to live long and independently

Our comprehensive market intelligence report provides a deep dive into the opportunities and challenges facing the aging in place industry – and explains why...

Longevity Science Summit: care of aging population talks continue

Our dive into Longevity Week's Science Summit continues... Last week, Longevity.Technology was lucky enough to attend Longevity Forum's Science Summit at Oxford's Oriel College, part...

Longevica raises $2.5 million for open research platform

$2.5m in funding to support longevity research platform and study to accelerate the discovery of life extension mechanisms, launching in 2022. Longevica, a life science...

    Subscribe to our newsletter